Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Keith

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
Cancer|July 11, 2019
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872Evanthia Galanis, S Keith Anderson, Erin L Twohy, et al.
Journal of Colloid and Interface Science|December 14, 2011
Effect of water-soluble polymers, polyethylene glycol and poly(vinylpyrrolidone), on the gelation of aqueous micellar solutions of Pluronic copolymer F127Nágila M P S Ricardo, Nadja M P S Ricardo, Flávia de M L L Costa, et al.
Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with BevacizumabRaymond Y Huang, Rifaquat Rahman, Karla V Ballman, et al.
Neuro-Oncology|December 21, 2014
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057KDaniel J Ma, Evanthia Galanis, S Keith Anderson, et al.
JAMA|July 27, 2016
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical TrialPaul D Brown, Kurt Jaeckle, Karla V Ballman, et al.
International Journal of Radiation Oncology, Biology, Physics|March 27, 2021
Initial Results of a Phase 2 Trial of <sup>18</sup>F-DOPA PET-Guided Dose-Escalated Radiation Therapy for GlioblastomaNadia Nicole Laack, Deanna Pafundi, S Keith Anderson, et al.
Nature Communications|November 28, 2024
Transcription factors ASCL1 and OLIG2 drive glioblastoma initiation and co-regulate tumor cell types and migrationBianca L Myers, Kathryn J Brayer, Luis E Paez-Beltran, et al.
Journal of the National Cancer Institute|May 23, 2018
Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic VirotherapyCheyne Kurokawa, Ianko D Iankov, S Keith Anderson, et al.
BMC Medical Genomics|December 22, 2010
Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platformMonica M Reinholz, Jeanette E Eckel-Passow, S Keith Anderson, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
Cancer|July 11, 2019
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872Evanthia Galanis, S Keith Anderson, Erin L Twohy, et al.
Journal of Colloid and Interface Science|December 14, 2011
Effect of water-soluble polymers, polyethylene glycol and poly(vinylpyrrolidone), on the gelation of aqueous micellar solutions of Pluronic copolymer F127Nágila M P S Ricardo, Nadja M P S Ricardo, Flávia de M L L Costa, et al.
Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with BevacizumabRaymond Y Huang, Rifaquat Rahman, Karla V Ballman, et al.
Neuro-Oncology|December 21, 2014
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057KDaniel J Ma, Evanthia Galanis, S Keith Anderson, et al.
JAMA|July 27, 2016
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical TrialPaul D Brown, Kurt Jaeckle, Karla V Ballman, et al.
International Journal of Radiation Oncology, Biology, Physics|March 27, 2021
Initial Results of a Phase 2 Trial of <sup>18</sup>F-DOPA PET-Guided Dose-Escalated Radiation Therapy for GlioblastomaNadia Nicole Laack, Deanna Pafundi, S Keith Anderson, et al.
Nature Communications|November 28, 2024
Transcription factors ASCL1 and OLIG2 drive glioblastoma initiation and co-regulate tumor cell types and migrationBianca L Myers, Kathryn J Brayer, Luis E Paez-Beltran, et al.
Journal of the National Cancer Institute|May 23, 2018
Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic VirotherapyCheyne Kurokawa, Ianko D Iankov, S Keith Anderson, et al.
BMC Medical Genomics|December 22, 2010
Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platformMonica M Reinholz, Jeanette E Eckel-Passow, S Keith Anderson, et al.
Pageof 14